The main purpose of this study is to assess the efficacy and safety of BT595 in adult subjects with chronic ITP. The primary objective of this study is to determine the rate of subjects with a response. BT595 is an immunoglobulin therapy that has many proposed methods of action that involve the suppression of immune response.